期刊
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
卷 95, 期 -, 页码 307-322出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2014.12.023
关键词
Diabetes mellitus; Diabetic retinopathy; Nanoparticles; Nanotechnology; Ocular drug delivery; Retinal neovascularization
资金
- Fundacao para a Ciencia e Tecnologia do Ministerio da Ciencia e Tecnologia (FCT, Portugal) [SFRH/BD/80335/2011]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/80335/2011] Funding Source: FCT
Diabetic retinopathy (DR) is a consequence of diabetes mellitus at the ocular level, leading to vision loss, and contributing to the decrease of patient's life quality. The biochemical and anatomic abnormalities that occur in DR are discussed in this review to better understand and manage the development of new therapeutic strategies. The use of new drug delivery systems based on nanoparticles (e.g. liposomes, dendrimers, cationic nanoemulsions, lipid and polymeric nanoparticles) is discussed along with the current traditional treatments, pointing out the advantages of the proposed nanomedicines to target this ocular disease. Despite the multifactorial nature of DR, which is not entirely understood, some strategies based on nanoparticles are being exploited for a more efficient drug delivery to the posterior segment of the eye. On the other hand, the use of some nanoparticles also seems to contribute to the development of DR symptoms (e.g. retinal neovascularization), which are also discussed in light of an efficient management of this ocular chronic disease. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据